* received any investigational drug, rdv, or other antiviral treatment for covid-19 * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 times the upper limit of normal * invasive mechanical ventilation, noninvasive mechanical ventilation, extracorporeal membrane oxygenation (ecmo), or renal replacement therapy (rrt) for acute kidney injury (aki) * positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding * known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply

* received any investigational drug, rdv, or other antiviral treatment for covid-19 * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 times the upper limit of normal * invasive mechanical ventilation, noninvasive mechanical ventilation, extracorporeal membrane oxygenation (ecmo), or renal replacement therapy (rrt) for acute kidney injury (aki) * positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding * known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply

received any investigational drug, rdv, or other antiviral treatment for covid-19 alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal invasive mechanical ventilation, noninvasive mechanical ventilation, extracorporeal membrane oxygenation (ecmo), or renal replacement therapy (rrt) for acute kidney injury (aki) positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply

received any investigational drug, rdv, or other antiviral treatment for covid-19 alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal invasive mechanical ventilation, noninvasive mechanical ventilation, extracorporeal membrane oxygenation (ecmo), or renal replacement therapy (rrt) for acute kidney injury (aki) positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply

- received any investigational drug, rdv, or other antiviral treatment for covid-19 - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal - invasive mechanical ventilation, noninvasive mechanical ventilation, ecmo, or rrt for acute kidney injury (aki) - positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding - known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply

- received any investigational drug, rdv, or other antiviral treatment for covid-19 - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 times the upper limit of normal - invasive mechanical ventilation, noninvasive mechanical ventilation, ecmo, or rrt for acute kidney injury (aki) - positive serum pregnancy test at screening for women of childbearing potential or currently breastfeeding - known hypersensitivity to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (sbecd) note: other protocol defined inclusion/exclusion criteria may apply